Empaglif 25

✔️ Dosage & Administration

• Recommended starting dose: 10 mg once daily, usually in the morning, with or without food.
• Dose increase: The dose may be increased to 25 mg once daily in patients who tolerate 10 mg and require additional blood glucose control, when appropriate.
• Assess kidney function and correct dehydration or volume depletion before starting treatment.
• Take the medicine consistently as prescribed. Do not change the dose without medical advice.

The appropriate dose and suitability of treatment depend on kidney function and the reason for prescribing empagliflozin.

✔️ Side Effects:

• Urinary tract infections.
• Genital fungal infections, including vaginal yeast infections and balanitis.
• Increased urination and thirst.
• Dehydration and low blood pressure.
• Dizziness or weakness.
• Low blood glucose, particularly when used with insulin or sulfonylureas.

✔️ Interaction

Empagliflozin may interact with the following medicines or monitoring methods:

• Diuretics: May increase urine output and the risk of dehydration or low blood pressure.
• Insulin and sulfonylureas: May increase the risk of hypoglycemia. The prescriber may need to adjust their doses.
• Urine glucose tests: These are not reliable for monitoring blood glucose during treatment because empagliflozin increases glucose excretion in urine.
• 1,5-Anhydroglucitol (1,5-AG) testing: Results may be unreliable during treatment with SGLT2 inhibitors. Alternative monitoring methods should be used.

✔️ Contraindications

Empaglif should not be used in patients with a known serious hypersensitivity to empagliflozin or any ingredient of the product.

Suitability in severe kidney impairment, end-stage kidney disease or dialysis depends on the approved product labeling and the intended indication. Kidney function must be assessed before treatment.

✔️ Pregnancy and Breastfeeding

Empagliflozin is generally not recommended during pregnancy, particularly during the second and third trimesters, because of potential risks to fetal kidney development. Consult a healthcare professional if pregnancy occurs or is planned.

Breastfeeding is generally not recommended during treatment because the potential effects on the infant are uncertain. A healthcare professional can advise on suitable alternatives.

✔️ Precautions and Warnings

• Kidney function: Assess kidney function before starting treatment and monitor it periodically. The glucose-lowering effect decreases as kidney function declines, and the appropriate eGFR threshold depends on the indication and current prescribing guidance.
• Dehydration and hypotension: Monitor for dizziness, faintness or low blood pressure, particularly in older adults and people taking diuretics.
• Diabetic ketoacidosis: This can occur even when blood glucose is not markedly elevated. Seek urgent medical care if symptoms develop.
• Genital and urinary infections: Report symptoms promptly and maintain good personal hygiene.
• Reduced food or fluid intake: Seek medical advice during severe illness, prolonged fasting or significant fluid loss, as temporary interruption may be necessary.
• Surgery: Inform the healthcare team before surgery or procedures involving prolonged fasting. Empagliflozin is generally withheld for at least three days before scheduled surgery when recommended by current prescribing guidance.

✔️ Storage:

Store below 30°C in a cool, dry place, protected from light and moisture. Keep out of the reach of children.